The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $12.93 in the prior trading day, Organon & Co (NYSE: OGN) closed at $9.45, down -26.91%. In other words, the price has decreased by -$26.91 from its previous closing price. On the day, 30.98 million shares were traded. OGN stock price reached its highest trading level at $10.879 during the session, while it also had its lowest trading level at $9.25.
Ratios:
Our goal is to gain a better understanding of OGN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.22. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.60. In the meantime, Its Debt-to-Equity ratio is 19.14 whereas as Long-Term Debt/Eq ratio is at 19.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on September 06, 2024, Downgraded its rating to Underweight and sets its target price to $20 from $18 previously.
On November 03, 2023, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $33 to $16.
On September 21, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $28.Barclays initiated its Overweight rating on September 21, 2023, with a $28 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 2437627392 and an Enterprise Value of 11696295936. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.83, and their Forward P/E ratio for the next fiscal year is 2.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 28.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 5.16. Its current Enterprise Value per Revenue stands at 1.827 whereas that against EBITDA is 6.627.
Stock Price History:
The Beta on a monthly basis for OGN is 0.70, which has changed by -0.518103 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $23.10, while it has fallen to a 52-week low of $10.45. The 50-Day Moving Average of the stock is -31.58%, while the 200-Day Moving Average is calculated to be -43.66%.
Shares Statistics:
The stock has traded on average 3.96M shares per day over the past 3-months and 7272370 shares per day over the last 10 days, according to various share statistics. A total of 259.96M shares are outstanding, with a floating share count of 259.08M. Insiders hold about 0.34% of the company’s shares, while institutions hold 81.33% stake in the company. Shares short for OGN as of 1744675200 were 17432896 with a Short Ratio of 4.40, compared to 1741910400 on 18361214. Therefore, it implies a Short% of Shares Outstanding of 17432896 and a Short% of Float of 9.0100005.
Dividends & Splits
In the trailing 12 months, OGN’s forward annual dividend rate was 0.0, compared to 1.12 this year. Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Organon & Co (OGN) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.93, with high estimates of $1.01 and low estimates of $0.77.
Analysts are recommending an EPS of between $4.22 and $3.66 for the fiscal current year, implying an average EPS of $3.86. EPS for the following year is $4.1, with 6.0 analysts recommending between $4.55 and $3.64.
Revenue Estimates
4 analysts predict $1.54B in revenue for the current quarter. It ranges from a high estimate of $1.6B to a low estimate of $1.49B. As of the current estimate, Organon & Co’s year-ago sales were $1.61BFor the next quarter, 4 analysts are estimating revenue of $1.56B. There is a high estimate of $1.59B for the next quarter, whereas the lowest estimate is $1.53B.
A total of 6 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.6B, while the lowest revenue estimate was $6.14B, resulting in an average revenue estimate of $6.29B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.38B in the next fiscal year. The high estimate is $6.79B and the low estimate is $6.07B.
